Aurobindo Pharma submits supplemental ANDA for Pregabalin
Aurobindo Pharma has submitted a supplemental Abbreviated New Drug Application (ANDA) for Pregabalin.
Asset / Drug
Drug and asset intelligence for Pregabalin with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.